RU2014143807A - Способ и прибор - Google Patents
Способ и прибор Download PDFInfo
- Publication number
- RU2014143807A RU2014143807A RU2014143807A RU2014143807A RU2014143807A RU 2014143807 A RU2014143807 A RU 2014143807A RU 2014143807 A RU2014143807 A RU 2014143807A RU 2014143807 A RU2014143807 A RU 2014143807A RU 2014143807 A RU2014143807 A RU 2014143807A
- Authority
- RU
- Russia
- Prior art keywords
- minutes
- active material
- pharmaceutically active
- pharmaceutical composition
- additive material
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 49
- 239000011149 active material Substances 0.000 claims abstract 24
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 17
- 239000013543 active substance Substances 0.000 claims abstract 10
- 230000002685 pulmonary effect Effects 0.000 claims abstract 7
- 230000009885 systemic effect Effects 0.000 claims abstract 2
- 239000000463 material Substances 0.000 claims 23
- 239000000654 additive Substances 0.000 claims 19
- 230000000996 additive effect Effects 0.000 claims 19
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 8
- 239000002245 particle Substances 0.000 claims 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims 6
- 229960002462 glycopyrronium bromide Drugs 0.000 claims 6
- 230000001143 conditioned effect Effects 0.000 claims 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 5
- 229910052751 metal Inorganic materials 0.000 claims 5
- 239000002184 metal Substances 0.000 claims 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 5
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 claims 4
- IREJFXIHXRZFER-PCBAQXHCSA-N indacaterol maleate Chemical compound OC(=O)\C=C/C(O)=O.N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 IREJFXIHXRZFER-PCBAQXHCSA-N 0.000 claims 4
- 229960004735 indacaterol maleate Drugs 0.000 claims 4
- 235000019359 magnesium stearate Nutrition 0.000 claims 4
- 229960000257 tiotropium bromide Drugs 0.000 claims 4
- 229960004026 vilanterol Drugs 0.000 claims 4
- DAFYYTQWSAWIGS-DEOSSOPVSA-N vilanterol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCOCC=2C(=CC=CC=2Cl)Cl)=C1 DAFYYTQWSAWIGS-DEOSSOPVSA-N 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 239000011246 composite particle Substances 0.000 claims 3
- 229960001375 lactose Drugs 0.000 claims 3
- 239000008101 lactose Substances 0.000 claims 3
- 150000003904 phospholipids Chemical class 0.000 claims 3
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 claims 2
- MDHKCIIEVIPVLU-JERHFGHZSA-M 4-[(1r)-2-[6-[2-[(2,6-dichlorophenyl)methoxy]ethoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol;diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol;bromide Chemical compound [Br-].C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCOCC=2C(=CC=CC=2Cl)Cl)=C1.C=1C=CC=CC=1C(C12CC[N+](CCOCC=3C=CC=CC=3)(CC1)CC2)(O)C1=CC=CC=C1 MDHKCIIEVIPVLU-JERHFGHZSA-M 0.000 claims 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical group O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 2
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 2
- 239000000808 adrenergic beta-agonist Substances 0.000 claims 2
- 229960004436 budesonide Drugs 0.000 claims 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims 2
- 235000013539 calcium stearate Nutrition 0.000 claims 2
- 239000008116 calcium stearate Substances 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 229960001469 fluticasone furoate Drugs 0.000 claims 2
- XTULMSXFIHGYFS-VLSRWLAYSA-N fluticasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 XTULMSXFIHGYFS-VLSRWLAYSA-N 0.000 claims 2
- 229960000289 fluticasone propionate Drugs 0.000 claims 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 2
- 229960000193 formoterol fumarate Drugs 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000003149 muscarinic antagonist Substances 0.000 claims 2
- 229960005018 salmeterol xinafoate Drugs 0.000 claims 2
- 229960004541 umeclidinium bromide Drugs 0.000 claims 2
- PEJHHXHHNGORMP-AVADPIKZSA-M umeclidinium bromide Chemical compound [Br-].C=1C=CC=CC=1C([C@@]12CC[N@@+](CCOCC=3C=CC=CC=3)(CC1)CC2)(O)C1=CC=CC=C1 PEJHHXHHNGORMP-AVADPIKZSA-M 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000133 mechanosynthesis reaction Methods 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 239000003380 propellant Substances 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F31/00—Mixers with shaking, oscillating, or vibrating mechanisms
- B01F31/80—Mixing by means of high-frequency vibrations above one kHz, e.g. ultrasonic vibrations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
- B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
- B02C19/00—Other disintegrating devices or methods
- B02C19/06—Jet mills
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2207/00—Methods of manufacture, assembly or production
- A61M2207/10—Device therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
- B01F2101/00—Mixing characterised by the nature of the mixed materials or by the application field
- B01F2101/22—Mixing of ingredients for pharmaceutical or medical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1205632.1A GB201205632D0 (en) | 2012-03-30 | 2012-03-30 | Method and apparatus |
| GB1205632.1 | 2012-03-30 | ||
| PCT/GB2013/050847 WO2013144655A1 (en) | 2012-03-30 | 2013-03-28 | Method and apparatus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014143807A true RU2014143807A (ru) | 2016-05-27 |
Family
ID=46159980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014143807A RU2014143807A (ru) | 2012-03-30 | 2013-03-28 | Способ и прибор |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150059746A1 (enExample) |
| EP (1) | EP2830751A1 (enExample) |
| JP (1) | JP2015516950A (enExample) |
| KR (1) | KR20140142264A (enExample) |
| CN (1) | CN104203385A (enExample) |
| AU (1) | AU2013239409A1 (enExample) |
| CA (1) | CA2867097A1 (enExample) |
| GB (1) | GB201205632D0 (enExample) |
| HK (1) | HK1206670A1 (enExample) |
| IL (1) | IL234659A0 (enExample) |
| IN (1) | IN2014DN08753A (enExample) |
| MX (1) | MX2014011795A (enExample) |
| NZ (1) | NZ629920A (enExample) |
| RU (1) | RU2014143807A (enExample) |
| SG (2) | SG11201405555RA (enExample) |
| WO (1) | WO2013144655A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9107851B2 (en) | 2012-10-15 | 2015-08-18 | New Jersey Institute Of Technology | Solventless mixing process for coating pharmaceutical ingredients |
| JP2015537025A (ja) * | 2012-11-16 | 2015-12-24 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 音響混合技術を使用して集塊物を作製するためのプロセス |
| US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| CN105473133A (zh) | 2013-04-30 | 2016-04-06 | 欧缇托匹克公司 | 干粉制剂及使用方法 |
| US20160235667A1 (en) * | 2013-10-02 | 2016-08-18 | Vectura Limited | Method and apparatus for making compositions for pulmonary administration |
| GB201321712D0 (en) * | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Dry Powder Inhaler |
| US20160317391A1 (en) * | 2013-12-17 | 2016-11-03 | Merck Sharp & Dohme Corp. | Media milling process for the manufacture of active pharmaceutical ingredients in propellants |
| ES2701525T3 (es) | 2014-07-09 | 2019-02-22 | Arven Ilac Sanayi Ve Ticaret As | Un procedimiento para la preparación de formulaciones para inhalación |
| SG11201700536XA (en) | 2014-09-09 | 2017-02-27 | Vectura Ltd | Formulation comprising glycopyrrolate, method and apparatus |
| EA201792159A1 (ru) | 2015-04-01 | 2018-01-31 | Люпин Атлантис Холдингс Са | Способ получения сухих порошкообразных смесей |
| US9968223B2 (en) | 2015-06-12 | 2018-05-15 | Sunbeam Products, Inc. | Blending appliance with paddle blade |
| HK1247150A1 (zh) * | 2015-07-07 | 2018-09-21 | Abbvie Inc. | 用声学混合自动造粒 |
| JPWO2017047650A1 (ja) * | 2015-09-14 | 2018-06-28 | 大和製罐株式会社 | 粉末吸入剤、吸入器、及び粉末吸入剤の製造方法 |
| EP3684338A4 (en) | 2017-09-22 | 2021-06-23 | Otitopic Inc. | DRY POWDER COMPOSITIONS WITH MAGNESIUM STEARATE |
| US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| US11642333B2 (en) * | 2019-05-23 | 2023-05-09 | Anovent Pharmaceutical (U.S.), Llc | Inhalable formulation of a solution containing vilanterol trifenatate and umeclidinium bromide |
| CN111297837B (zh) * | 2020-03-26 | 2022-02-22 | 上海方予健康医药科技有限公司 | 一种干粉吸入剂的制备方法 |
| CN113144997B (zh) * | 2021-03-23 | 2022-10-25 | 西安近代化学研究所 | 共振声混合中临界波动率确定、混合均匀性判定方法及系统 |
| KR102796431B1 (ko) * | 2021-09-17 | 2025-04-16 | 주식회사 케이티앤지 | 흡연 물품 및 에어로졸 발생 시스템 |
| US12157098B2 (en) * | 2021-12-14 | 2024-12-03 | Honeywell Federal Manufacturing & Technologies, Llc | Resonant acoustic mixing system and method |
| US20250235399A1 (en) * | 2022-04-07 | 2025-07-24 | Board Of Regents, The University Of Texas System | Methods of preparing carrier-based dry powders for inhalation |
| EP4531809A2 (en) * | 2022-05-28 | 2025-04-09 | Avalyn Pharma Inc. | Nintedanib and nintedanib combination dry powder compositions and uses |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996025918A1 (en) * | 1995-02-24 | 1996-08-29 | Nanosystems L.L.C. | Aerosols containing nanoparticle dispersions |
| US20070212422A1 (en) * | 1999-11-10 | 2007-09-13 | Manfred Keller | Dry powder for inhalation |
| JP2004533917A (ja) * | 2001-05-01 | 2004-11-11 | グラクソ グループ リミテッド | 解塊装置および方法 |
| GB0205327D0 (en) * | 2002-03-06 | 2002-04-17 | Glaxo Group Ltd | compounds |
| US8501232B2 (en) * | 2002-04-23 | 2013-08-06 | Nanotherapeutics, Inc. | Process of forming and modifying particles and compositions produced thereby |
| US7188993B1 (en) * | 2003-01-27 | 2007-03-13 | Harold W Howe | Apparatus and method for resonant-vibratory mixing |
| US20060152998A1 (en) * | 2003-09-10 | 2006-07-13 | Burr Ronald F | Acoustic fluidized bed |
| GB0321607D0 (en) * | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
| GB0605676D0 (en) * | 2006-03-22 | 2006-05-03 | Vectura Ltd | Improvements in extraction of powder formulations |
| EP2082767A1 (en) * | 2008-01-24 | 2009-07-29 | Vectura Delivery Devices Limited | Inhaler |
| WO2009158300A1 (en) * | 2008-06-26 | 2009-12-30 | 3M Innovative Properties Company | Dry powder pharmaceutical compositions for pulmonary administration, and methods of manufacturing thereof |
| CN102149437B (zh) * | 2008-07-18 | 2017-02-15 | 普罗索尼克斯有限公司 | 用于提高氟替卡松颗粒结晶度的方法 |
| HUE038555T2 (hu) * | 2010-04-21 | 2018-10-29 | Chiesi Farm Spa | Eljárás csökkentett elektrosztatikus töltéssel rendelkezõ részecskék elõállítására |
| WO2011136363A1 (ja) | 2010-04-28 | 2011-11-03 | 三洋電機株式会社 | 回路装置の製造方法 |
| US9763965B2 (en) * | 2012-04-13 | 2017-09-19 | Glaxosmithkline Intellectual Property Development Limited | Aggregate particles |
| JP2015537025A (ja) * | 2012-11-16 | 2015-12-24 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 音響混合技術を使用して集塊物を作製するためのプロセス |
-
2012
- 2012-03-30 GB GBGB1205632.1A patent/GB201205632D0/en not_active Ceased
-
2013
- 2013-03-28 SG SG11201405555RA patent/SG11201405555RA/en unknown
- 2013-03-28 JP JP2015502460A patent/JP2015516950A/ja active Pending
- 2013-03-28 MX MX2014011795A patent/MX2014011795A/es unknown
- 2013-03-28 CN CN201380016626.5A patent/CN104203385A/zh active Pending
- 2013-03-28 US US14/387,629 patent/US20150059746A1/en not_active Abandoned
- 2013-03-28 AU AU2013239409A patent/AU2013239409A1/en not_active Abandoned
- 2013-03-28 WO PCT/GB2013/050847 patent/WO2013144655A1/en not_active Ceased
- 2013-03-28 RU RU2014143807A patent/RU2014143807A/ru not_active Application Discontinuation
- 2013-03-28 NZ NZ629920A patent/NZ629920A/en not_active IP Right Cessation
- 2013-03-28 HK HK15107349.6A patent/HK1206670A1/xx unknown
- 2013-03-28 CA CA2867097A patent/CA2867097A1/en not_active Abandoned
- 2013-03-28 KR KR1020147027247A patent/KR20140142264A/ko not_active Withdrawn
- 2013-03-28 EP EP13715413.4A patent/EP2830751A1/en not_active Withdrawn
- 2013-03-28 SG SG10201608088YA patent/SG10201608088YA/en unknown
-
2014
- 2014-09-15 IL IL234659A patent/IL234659A0/en unknown
- 2014-10-17 IN IN8753DEN2014 patent/IN2014DN08753A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL234659A0 (en) | 2014-11-30 |
| HK1206670A1 (en) | 2016-01-15 |
| KR20140142264A (ko) | 2014-12-11 |
| EP2830751A1 (en) | 2015-02-04 |
| WO2013144655A1 (en) | 2013-10-03 |
| MX2014011795A (es) | 2015-01-12 |
| JP2015516950A (ja) | 2015-06-18 |
| GB201205632D0 (en) | 2012-05-16 |
| SG10201608088YA (en) | 2016-11-29 |
| IN2014DN08753A (enExample) | 2015-05-22 |
| NZ629920A (en) | 2017-03-31 |
| CN104203385A (zh) | 2014-12-10 |
| AU2013239409A1 (en) | 2014-09-25 |
| SG11201405555RA (en) | 2014-11-27 |
| CA2867097A1 (en) | 2013-10-03 |
| US20150059746A1 (en) | 2015-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240252440A1 (en) | Compositions, methods and systems for aerosol drug delivery | |
| RU2012145762A (ru) | Способ получения частиц с пониженным электростатическим зарядом | |
| US20170071850A1 (en) | Compositions for respiratory delivery of active agents and associated methods and systems | |
| EP1660035A2 (en) | Liquid compositions comprising formoterol | |
| JP2004532217A (ja) | 霧状化を経て肺に送達するためのフォルモテロール含有エアゾール組成物 | |
| CA2749231A1 (en) | Pharmaceutical composition for inhalation | |
| RU2013106866A (ru) | Фармацевтические композиции | |
| CA2912927A1 (en) | Compositions, methods & systems for respiratory delivery of three or more active agents | |
| RU2012138909A (ru) | Фармацевтическая порошковая композиция для ингаляций | |
| EP2682102A2 (en) | Inhalation Compositions Comprising Corticosteroid and Sorbitol | |
| EP2682098A2 (en) | Inhalation Compositions | |
| RU2582218C2 (ru) | Способ получения дозирующего распыляющего ингалятора для лечения респираторного заболевания | |
| US20150352077A1 (en) | Multi-Component Crystalline Particles for Inhalation Therapy | |
| EP3082708B1 (en) | Media milling process for the manufacture of active pharmaceutical ingredients in propellants | |
| KR20180101438A (ko) | 7-아조니아바이사이클로[2.2.1]헵탄 유도체의 건조 분말 흡입기 조성물 | |
| EP3166594B1 (en) | A process for preparing the inhalation formulations | |
| US20250057764A1 (en) | Compositions, methods and systems for aerosol drug delivery | |
| JP6653323B2 (ja) | 吸入可能な製剤 | |
| NZ742474A (en) | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic | |
| NZ742474B2 (en) | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20171023 |